Myasthenia Gravis Related Research Tools

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane. Localized or general muscle weakness is the predominant symptom and is induced by the antibodies. Traditionally, most patients with MG require induction therapy with high doses of corticosteroids and maintenance with an immunosuppressant. Nowadays, biologics are emerging as important therapeutic tools that provide better corticosteroid-sparing effects than standard treatments and can even induce remission.

As shown in Fig.1, immunotherapeutics that target different elements in these pathways are shown in yellow boxes. The AChR is presented to CD4+ T cells by antigen-presenting cells (APCs) via co-stimulatory molecules. Downstream upregulation of cytokines stimulates B cells to produce anti-AChR antibodies that lead to the destruction of AChRs by fixing complement at the neuromuscular endplate region. Levels of regulatory T (Treg) and T helper (TH) 17 cells and cytokines are increased in patients with MG, thereby causing the immune imbalance.

Several biologic agents have shown promising effects in studies of their efficacy in MG to date. The success suggests that the emergence of new molecular targets could bring a revolution in the treatment of MG. Creative Biolabs has screened the most popular targets and provides high-quality products as well as customized services for our clients. For more services and products, please contact us.

CD19	CD20	CD80	CD86
IL-2	IL-4	IL-6	IL-17
IL-22	JAK1	JAK2	JAK3
AchR	PD-1	PD-L1	CTLA4
C5	C3	TNF	B cell trophic factor (BAFF)

For Research Use Only. Not For Clinical Use.

Target

Synaptogyrin

Polyubiquitin (K63-linkage)

Pan-KCHIP

GFAP

ENPP5

Mitofusin 2

FOXG1

Glypican 1

CDK3

PKC Delta

ABCA4 Rim Protein

LC3B

ALS2CR1

CRMP5

CacyBP

Monoamine Oxidase B

NRG3

NQO1

ALS2CR2

BACE2

CLN5

AHNAK

FABP3

Mu Opioid Receptor

SOD2

NALP

Insulin Receptor Beta

OPA1

GPRC5A

ATOH1

Doublecortin

PRKAR2A